| | Characteristic | Agranulocytosis cases
| Control cases
| value |
| Age (yr)
Mean (SD) | 42.3 (10.1) | 41 (13.8) | 0.30 | | Female sex, N (%) | 20 (95.2) | 59 (72.8) | | | Antithyroid drug, N (%) | | | 0.66 | | PTU | 2 (9.5) | 8 (9.9) | | | MMI | 19 (90.5) | 73 (90.0) | | | ATD duration, N (%) | | | n/a | | <3 months | 18 (85.7) | 0 | | | 3–18 months | 2 (9.5) | 34 (42.0) | | | >18 months | 1 (4.8) | 47 (58.0) | | Initial ATD dose
Mean (SD) | | | | | PTU (mg/d) | 250 (70.7) | 287.5 (115.7) | 0.60 | | MMI (mg/d) | 18.9 (5.9) | 20.5 (5.7) | 0.30 | Dose of ATD at the time of recruitment
Mean (SD) | | | n/a | | PTU (mg/d) | 250 (70.7) | 75 (37.8) | | | MMI (mg/d) | 20.5 (5.6) | 8.8 (4.8) | | | Fever, N (%) | 20 (95.2) | n/a | | | Sore throat, N (%) | 13 (62.0) | n/a | | Mean granulocytes at the time of recruitment (cell/μL)
Mean (SD) | 170 (35.2) | 4255.3 (173.7) | n/a | Thyroid hormone at the time of recruitment
Median (Q1-Q3) | | | | | FT3 (pg/mL) | 6.49 (2.7–14.45) | 3.6 (2.8–7.1) | 0.001 | | FT4 (pg/mL) | 42.65 (15.07–65.83) | 12.6 (8.8–25.5) | 0.0001 | | TSH (mIU/L) | 0.01 (0.004–0.14) | 0.058 (0.004–2.37) | 0.156 | Recover period (day)
Median (Q1–Q3) | 5 (3–7) | n/a | | | Death, N (%) | 2 (9.5) | n/a | |
|
|
